Loading...
XNAS
ISPC
Market cap2mUSD
Dec 05, Last price  
0.48USD
1D
-0.54%
1Q
-43.38%
IPO
-99.68%
Name

iSpecimen Inc

Chart & Performance

D1W1MN
XNAS:ISPC chart
P/E
P/S
0.29
EPS
Div Yield, %
Shrs. gr., 5y
-35.89%
Rev. gr., 5y
16.67%
Revenues
9m
-6.42%
4,394,8184,298,3508,184,10611,135,30310,402,3039,928,1849,291,115
Net income
-12m
L+12.60%
-5,347,052-4,727,050-6,758,533-10,015,968-9,040,723-11,099,488-12,497,805
CFO
-8m
L+42.29%
-2,681,749-2,679,900-288,380-10,668,410-5,817,720-5,807,550-8,263,713

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
IPO date
Jun 17, 2021
Employees
75
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT